FRM
ADVM

Fox Run Management’s Adverum Biotechnologies ADVM Stock Holding History

Fox Run Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,510
Closed -$80K – 547
2018
Q2 		$80K Buy
1,510
+418
+38% +$25.1K 0.03% 628
2018
Q1 		$63K Buy
+1,092
New +$68K 0.02% 689

Other funds holding ADVM

MSU
Mizuho Securities USA New York $4.24B AUM 22.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
WM
WS Management Jacksonville, Florida $1.13B AUM 53.44% 1-Year Est. Return
CHP
Castle Hook Partners New York $23.4B AUM 158.96% 1-Year Est. Return

Fox Run Management's ADVM Position: Q3 2018 in Review

Fox Run Management sold out of Adverum Biotechnologies (ADVM) in Q3 2018, closing a stake of 1,510 shares — an estimated $80K sold.

Fox Run Management first reported a position in ADVM in Q1 2018 and held it in 2 quarters. The position peaked at $80K in Q2 2018. 101 funds tracked by Wall St. Rank hold ADVM as of Q3 2018.

  • Fox Run Management reported no remaining Adverum Biotechnologies position as of Q3 2018 after selling out during the quarter.
  • Fox Run Management sold 1,510 Adverum Biotechnologies shares in Q3 2018, an estimated $80K.
  • Fox Run Management first reported a position in Adverum Biotechnologies in Q1 2018 and held it in 2 quarters.
  • Fox Run Management's Adverum Biotechnologies position peaked at $80K in Q2 2018.
  • 101 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2018.

Based on Fox Run Management's 13F filing for Q3 2018, filed 5 Oct 2018.